Follicular Lymphoma Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight

FelveInsight's "Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Follicular Lymphoma Market Report:
• The Follicular Lymphoma market size across the 7MM is projected to rise from USD 1,702 million in 2025 to approximately USD 3,081 million by 2034, reflecting a CAGR of 6.8%.
• In March 2026, Knight Therapeutics Inc. has announced that its Argentine subsidiary, Laboratorio LKM S.A., and its Mexican subsidiary, Grupo Biotoscana de Especialidad S.A. de C.V., have filed a supplemental application with Administración Nacional de Medicamentos, Alimentos y Tecnología Médica and Comisión Federal para la Protección contra Riesgos Sanitarios. The submission seeks approval for an expanded indication of MINJUVI, to be used in combination with lenalidomide and rituximab, for treating adult patients with relapsed or refractory follicular lymphoma (Grade 1-3a) who have received at least one prior systemic therapy.
• In November 2025, AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp), a subcutaneously administered T-cell-engaging bispecific antibody, in combination with rituximab and lenalidomide (EPKINLY + R2) for treating adult patients with relapsed or refractory follicular lymphoma (FL). The approval is supported by pivotal Phase 3 EPCORE® FL-1 trial results, which compared the fixed-duration EPKINLY + R2 regimen to the standard R2 therapy. Findings highlight the combination's potential to significantly advance FL management and enable earlier patient access to innovative treatment options.
• In September 2025, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a subcutaneous (SC) formulation of mosunetuzumab (Lunsumio) for adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The European Commission is expected to make a final decision soon. This recommendation is based on the primary analysis of the Phase 1/2 GO29781 study (NCT02500407), which showed that patients treated with the SC formulation achieved an overall response rate (ORR) of 74.5% (95% CI, 64.4%-82.9%) and a complete response (CR) rate of 58.5% (95% CI, 47.9%-68.6%) as assessed by an independent review committee
• In August 2025, Results from the Phase III EPCORE FL-1 trial (NCT05409066) indicate that Genmab's bispecific antibody Epkinly (epcoritamab) showed promising efficacy when combined with Rituxan (rituximab) and Revlimid (lenalidomide) (R2) in patients with relapsed or refractory (R/R) follicular lymphoma (FL). The company reported that this combination led to statistically significant improvements in both overall response rate (ORR) and progression-free survival (PFS).
• In June 2025, The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for treating patients with relapsed or refractory follicular lymphoma, as announced by the agency. This approval is based on findings from the phase 3 inMIND trial (NCT04680052), a double-blind, placebo-controlled study. In the trial, 548 patients with relapsed or refractory follicular lymphoma were randomly assigned to receive either the newly approved combination or a placebo along with lenalidomide and rituximab.
• In March 2025, The European Commission (EC) has granted approval for lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-targeting CAR T-cell therapy, for use in adult patients with relapsed or refractory follicular lymphoma who have undergone at least two prior lines of systemic treatment, according to a press release by Bristol Myers Squibb.
• In February 2025, Genmab A/S (Nasdaq: GMAB) has announced that Japan's Ministry of Health, Labour and Welfare has granted approval for EPKINLY® (epcoritamab) to treat relapsed or refractory (R/R) follicular lymphoma (FL; Grades 1 to 3A) in patients who have received at least two previous lines of therapy. With this expanded approval, EPKINLY becomes the first and only subcutaneous T-cell engaging bispecific antibody authorized in Japan for use in both R/R FL and R/R large B-cell lymphomas-including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma-after two or more prior treatments.
• In December 2024, At the 2024 American Society of Hematology (ASH) Annual Meeting, AstraZeneca presented interim results from a first-in-human trial investigating AZD0486, an innovative bispecific T-cell engager (BiTE), in patients with relapsed or refractory follicular lymphoma (r/r FL).
• In August 2024, The company intends to file a supplemental Biologics License Application (sBLA) for tafasitamab by the end of 2024 to treat patients with follicular lymphoma (FL) who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on favorable Phase III trial outcomes.
• In June 2024, A consortium headed by Eugene Private Equity and Korea Development Bank Private Equity revealed its intention to acquire an 80% ownership stake in South Korean vaccine producer Boryung Biopharma Co. for 320 billion won (around USD 231 million).
• Approximately 90% of Follicular Lymphomas possess one or more mutations in genes involved in epigenetic regulation through histone modifications (KMT2D, CREBBP, and EZH2) and chromatin remodelling (HIST1H1B-E,ARID1A), according to a research by Perrett and Okosun (2021). KMT2D, CREBBP, and EP300 are present in 60-80%, 70%, and 15%, respectively, of FL cases
• In accordance with a research by Liu W. et al. (2021), 10-20% of patients receiving immunochemotherapy relapse after 24 months of diagnosis, and these patients fare much worse than those who do not. Low, moderate, and high risk were distributed at 36%, 37%, and 27%, respectively
• Incidence cases of Follicular Lymphoma are roughly 3,300, 2,900, 2,800, 1,700, and 2,800 in Germany, France, Italy, Spain, and the UK, respectively, according to a study by Kanas et al. (2021).
• With tremendous success over the years, businesses all around the world are diligently working towards the creation of revolutionary remedies. The management of FL is showing promise from major players like Novartis Pharmaceuticals, Genentech/Roche, Xynomic Pharmaceuticals, MEI Pharma, Epizyme, Innovent Biologics, etc.
• Some of the most eagerly anticipated new medicines that are pending approval include Kymriah (tisagenlecleucel), ME-401, Abexinostat, Tazemetostat, Parsaclisib (IBI376), and others.
• Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, AstraZeneca, Incyte Corp, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Eli Lilly and Company, ADC Therapeutics S.A, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
• Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
• The Follicular Lymphoma epidemiology based on risk analyzed that low risk, intermediate risk and high risk patients contribute to 20%, 53% and 27% of all FL cases, respectively
• The Follicular Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.

Follicular Lymphoma Overview
Follicular Lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), which is a cancer of the lymphatic system. It originates from B lymphocytes (B cells), a type of white blood cell that plays a crucial role in the immune system. Follicular Lymphoma is characterized by the formation of abnormal, usually slow-growing, lymphoid follicles in the lymph nodes.

Get a Free sample for the Follicular Lymphoma Market Report:
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Follicular Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Follicular Lymphoma Epidemiology Segmentation:
The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Follicular Lymphoma
• Prevalent Cases of Follicular Lymphoma by severity
• Gender-specific Prevalence of Follicular Lymphoma
• Diagnosed Cases of Episodic and Chronic Follicular Lymphoma

Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ Follicular Lymphoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Follicular Lymphoma Therapies and Key Companies
• LUNSUMIO (mosunetuzumab): Roche
• BRUKINSA (zanubrutinib): BeiGene
• YESCARTA: Kite Pharma
• MONJUVI (tafasitamab): Incyte Corporation
• AZD0486: AstraZeneca
• Abexinostat: Xynomic Pharmaceuticals
• ME-401: MEI Pharma
• Tisagenlecleucel: Novartis
• Parsaclisib (IBI376): Innovent Biologics
• Odronextamab: Regeneron
• Mosunetuzumab: Genetech
• Abexinostat: Xynomic Pharma
• Rituximab IV: Roche
• Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche
• Enzastaurin: Eli Lilly and Company
• Loncastuximab tesirine: ADC Therapeutics S.A
• Zanubrutinib: BeiGene
• Bendamustine: Cephalon
• Tazemetostat: Epizyme, Inc.
• ibrutinib: Pharmacyclics LLC.
• Obatoclax mesylate: Gemin X
• Ibrutinib: AbbVie
• IXAZOMIB: Millennium Pharma

To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Follicular Lymphoma Market Drivers
• Rising prevalence of indolent lymphomas: Increasing incidence of follicular lymphoma, particularly among aging populations, is expanding the patient pool
• Advancements in targeted therapies: Growth in targeted treatments such as PI3K inhibitors, EZH2 inhibitors, and monoclonal antibodies is improving outcomes
• Emergence of immunotherapies: CAR-T cell therapies and bispecific antibodies are transforming treatment paradigms and driving market growth
• Strong pipeline and ongoing clinical trials: Robust R&D activity with novel agents and combination therapies enhances future market potential
• Increased adoption of combination regimens: Use of chemoimmunotherapy and targeted combinations improves progression-free survival

Follicular Lymphoma Market Barriers
• High cost of novel therapies: Advanced treatments like CAR-T and biologics are expensive, limiting accessibility
• Relapse and disease recurrence: Frequent relapses require repeated treatment, complicating disease management
• Adverse effects and safety concerns: Toxicities associated with therapies (e.g., cytokine release syndrome in CAR-T) impact patient compliance
• Limited curative options: Despite treatment advances, follicular lymphoma remains largely incurable
• Heterogeneity of disease biology: Variability in patient response complicates treatment standardization
• Stringent regulatory requirements: Complex clinical trial designs and long approval timelines delay new product entry

Scope of the Follicular Lymphoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, AstraZeneca, Incyte Corp, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Eli Lilly and Company, ADC Therapeutics S.A, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
• Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Follicular Lymphoma Unmet Needs, KOL's views, Analyst's views, Follicular Lymphoma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.